Vanguard Global Advisers’s Summit Therapeutics SMMT Stock Holding History
Bought
Maintained
Sold
Other funds holding SMMT
BBA
KCM
Vanguard Global Advisers's SMMT Position: Q3 2026 in Review
Vanguard Global Advisers increased its Summit Therapeutics (SMMT) stake by 4.7% in Q3 2026, buying an estimated $41.4K and bringing the position to 61,876 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #1685.
Vanguard Global Advisers first reported a position in SMMT in Q1 2026 and has held it in 3 quarters since. The position peaked at $1.16M in Q1 2026. 298 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.
- Vanguard Global Advisers held 61,876 shares of Summit Therapeutics worth $1.05M as of Q3 2026.
- Vanguard Global Advisers bought 2,771 Summit Therapeutics shares in Q3 2026, an estimated $41.4K.
- Summit Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #1685 holding.
- Vanguard Global Advisers first reported a position in Summit Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Global Advisers's Summit Therapeutics position peaked at $1.16M in Q1 2026.
- 298 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.
Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.